Our results reveal a frequency of approximately one out of seven cases to exhibit immunoreactivity for PD-L1 in the invasive tumor, of which roughly one third (5% of the whole cohort) showed a higher expression with a TPS of at least 10%. Here, CD274 is linked to neoplasm.